Performance Measurement Network

Question: What dosage of Lovenox is suffiecient to meet antithrombotic therapy administered by end of hospital day 2

FY11Q1 Antithrombotic therapy administered by end of hospital day 2….Would Lovenox 40 mg sub-Q bid be sufficient to answer "Yes" for antithrombotic therapy administered by end of hospital day 2? If not, what dose of Lovenox would satisfy the measure?


Lovenox administered the day of or after hospital arrival will meet STK-5, select 'Yes'. See Appendix C, Table 8.2 "Antithrombotic Medications for Stroke" in the specifications manual.

Anticoagulants at doses to prevent VTE are considered insufficient antithrombotic therapy to prevent recurrent ischemic stroke or TIA; however,drug dosages are not used in the measure rate calculation. The clinical practice guideline supporting this measure recommends aspirin 325 mg.

Question Details
Focus area(s): Chart Abstracted Measure Specifications – Clinical
Related documents: STK-05, Antithrombotic Therapy Administered by End of Hospital Day Two, ,

Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Performance Measurement Network? Send feedback
This website is using cookies. More info. That's Fine